Evidence map›Paper›PMID 38051587›Full record

ArticleThe Journal of clinical investigation2024

Single-cell sequencing reveals Hippo signaling as a driver of fibrosis in hidradenitis suppurativa.

Kelsey R van Straalen, Feiyang Ma, Pei-Suen Tsou, Olesya Plazyo, Mehrnaz Gharaee-Kermani, Marta Calbet, Xianying Xing, Mrinal K Sarkar, Ranjitha Uppala, Paul W Harms and 20 more

Open access · goldAbstract read
In one paragraph

Article in The Journal of clinical investigation, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed, 1 pooled it
12.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 1 synthesis or guideline pooled it, 44 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Inflammatory niches as spatial drivers of disease mechanisms and targets for personalized treatment.Journal of the European Academy of Dermatology and Venereology : JEADV · 2026
    Review
  14. Article
  15. Review
  16. Review
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

30 authors at 6 institutions in 5 countries.

Kelsey R van StraalenDepartment of Dermatology and.
Feiyang MaDivision of Rheumatology, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, Michigan, USA.
Pei-Suen TsouDivision of Rheumatology, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, Michigan, USA.
Olesya PlazyoDepartment of Dermatology and.
Mehrnaz Gharaee-KermaniDepartment of Dermatology and.
Marta CalbetAlmirall SA, R&D Center, Sant Feliu de Llobregat, Barcelona, Spain.
Xianying XingDepartment of Dermatology and.
Mrinal K SarkarDepartment of Dermatology and.
Ranjitha UppalaDepartment of Dermatology and.
Paul W HarmsDepartment of Dermatology and.
Rachael WasikowskiDepartment of Dermatology and.
Lina NahlawiDepartment of Dermatology and.
Mio NakamuraDepartment of Dermatology and.
Milad EshaqDepartment of Dermatology and.
Cong WangLaboratory for Experimental Immunodermatology, Department of Dermatology, Erasmus University Medical Center, Rotterdam, Netherlands.
Craig DobryDepartment of Dermatology and.
Jeffrey H KozlowDivision of Plastic Surgery, Department of Surgery, and.
Jill Cherry-BukowiecSection of General Surgery, Department of Surgery, University of Michigan Medical School, Ann Arbor, Michigan, USA.
William D BrodieDivision of Rheumatology, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, Michigan, USA.
Kerstin WolkInterdisciplinary group Molecular Immunopathology, Dermatology/Medical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany.
Özge UluçkanAlmirall SA, R&D Center, Sant Feliu de Llobregat, Barcelona, Spain.
Megan N MattichakDivision of Rheumatology, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, Michigan, USA.
Matteo PellegriniDepartment of Molecular, Cell, and Developmental Biology and.
Robert L ModlinDepartment of Dermatology, UCLA, Los Angeles, California, USA.
Emanual MaverakisDepartment of Dermatology, University of California, Sacramento, California, USA.
Robert SabatInterdisciplinary group Molecular Immunopathology, Dermatology/Medical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany.
J Michelle KahlenbergDepartment of Dermatology and.
Allison C BilliDepartment of Dermatology and.
Lam C TsoiDepartment of Dermatology and.
Johann E GudjonssonDepartment of Dermatology and.
University of Michigan · USAlmirall (Spain) · ESCharité - Universitätsmedizin Berlin · DEUniversity of California, Los Angeles · USCalifornia State University, Sacramento · USErasmus MC · NL

Funding

Molecular Analysis of the Host Immune Response in LeprosyR01AI022553 · NIAID · UNIVERSITY OF SOUTHERN CALIFORNIA · PI ROBERT L MODLIN · 1989 to 2026
$15.7M
TCR GAMMA/DELTA LYMPHOCYTES IN HUMAN SKIN LESIONSR01AR040312 · NIAMS · UNIVERSITY OF SOUTHERN CALIFORNIA · PI MODLIN, ROBERT L · 1990 to 2025
$10.4M
Microbiology and Metagenomics CoreP50AR080594 · NIAMS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ROBERT L MODLIN · 2022 to 2026
$9.2M
University of Michigan Skin Biology and Diseases Resource-based CenterP30AR075043 · NIAMS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI ANDRZEJ A. DLUGOSZ · 2019 to 2026
$6.6M
Kallikrein-PAR interactions in skin inflammationR01AR073196 · NIAMS · VANDERBILT UNIVERSITY MEDICAL CENTER · PI WARD, NICOLE LEANNE · 2018 to 2023
$3.3M
The skin microbiome in acneR01AR074302 · NIAMS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI GALLO, RICHARD L, MODLIN, ROBERT L · 2018 to 2022
$2.6M
Hippo signaling as a critical regulator of lupus keratinocyte dysfunctionR01AR081640 · NIAMS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Joanne Michelle Kahlenberg · 2022 to 2026
$2.4M
Role of IL-13 and the IL-13 Associated rs20541 Risk Variant in the Pathogenesis of PsoriasisR01AR069071 · NIAMS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI GUDJONSSON, JOHANN ELI · 2015 to 2019
$2.1M
Mechanisms of sex discrepancy in autoimmune disease: Regulation of the female-biased VGLL3 immune pathwayK08AR078251 · NIAMS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI BILLI, ALLISON CHELSA · 2021 to 2025
$865k
Integrative Biology Approach to Identify and Characterize Roles of lncRNAs Associated with Psoriasis PathologyK01AR072129 · NIAMS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI TSOI, LAM CHEUNG · 2017 to 2021
$500k
NIAID NIH HHS R01 AI022553NIAMS NIH HHS K01 AR072129NIAMS NIH HHS K08 AR078251NIAMS NIH HHS P30 AR075043NIAMS NIH HHS P50 AR080594NIAMS NIH HHS R01 AR040312NIAMS NIH HHS R01 AR069071NIAMS NIH HHS R01 AR073196NIAMS NIH HHS R01 AR074302NIAMS NIH HHS R01 AR081640
6 · The paper itself

Abstract

Hidradenitis suppurativa (HS) is a chronic inflammatory disease characterized by abscesses, nodules, dissecting/draining tunnels, and extensive fibrosis. Here, we integrate single-cell RNA sequencing, spatial transcriptomics, and immunostaining to provide an unprecedented view of the pathogenesis of chronic HS, characterizing the main cellular players and defining their interactions. We found a striking layering of the chronic HS infiltrate and identified the contribution of 2 fibroblast subtypes (SFRP4+ and CXCL13+) in orchestrating this compartmentalized immune response. We further demonstrated the central role of the Hippo pathway in promoting extensive fibrosis in HS and provided preclinical evidence that the profibrotic fibroblast response in HS can be modulated through inhibition of this pathway. These data provide insights into key aspects of HS pathogenesis with broad therapeutic implications.

Indexed as

Hidradenitis SuppurativaFibrosisHippo Signaling PathwayHumansCytokinesDermatologyFibrosisInflammationSkin

Identifiers

PMID38051587
PMCPMC10836805
OpenAlexW4389334259

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.